Tools for Practice Outils pour la pratique


#342 Triglyce-Ride that High?


CLINICAL QUESTION
QUESTION CLINIQUE
Do triglyceride-lowering medications (fibrates, statins, niacin, omega-3s) reduce the risk of pancreatitis in patients with hypertriglyceridemia?


BOTTOM LINE
RÉSULTAT FINAL
No randomized controlled trials (RCTs) have assessed the effect of fibrates or any other triglyceride-lowering medication on pancreatitis risk in patients with “very high” triglycerides (≥5.6 mmol/L). In patients with triglycerides <5.6 mmol/L, fibrates either have no effect on pancreatitis or increase the absolute risk by ~0.1% over 5 years, whereas statins lower the risk by 0.1%.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • No RCT examined triglyceride-lowering medications in patients with triglycerides ≥5.6 mmol/L.
  • Systematic review1 of cardiovascular RCTs of fibrates (7 RCTs, 40,162 patients, average baseline triglycerides 1.6-2.1 mmol/L) and statins (21 RCTs, 153,414 patients, average baseline triglycerides 1.3-2.1 mmol/L):
    • Pancreatitis at ~5 years (differences statistically significant):
      • Fibrates: 0.4% versus 0.3% with placebo.
      • Statins: 0.2% versus 0.3% with placebo.
    • Largest RCT2 (not included in above review) compared pemafibrate (not available in Canada) to placebo in 10,497 patients with type 2 diabetes, fasting triglycerides 2.0-5.5 mmol/L (median 3.1 mmol/L), and high-density-lipoprotein cholesterol <1.0 mmol/L. After 3.4 years:
      • Pancreatitis: 0.5% in both groups.
    • No evidence for niacin or omega-3 fatty acids on pancreatitis risk in any triglyceride group

CONTEXT
CONTEXTE
  • Alcohol overuse and gallstones account for the majority of acute pancreatitis,3,4 whereas hypertriglyceridemia account for <5% of cases.4,5
    • Fibrates (except possibly pemafibrate)2 increase risk of developing gallstones by ~1% over 6 years,6-8 potentially explaining how they lead to a net increase in pancreatitis.
  • Guidelines recommend fibrates to lower triglyceride-related pancreatitis risk in patients with “elevated” triglycerides, but differ in threshold triglyceride levels to consider treating (5.6-11.2 mmol/L).9-10
  • In a cohort study of 1.5 million patients, the 5-year risk of acute pancreatitis based on triglyceride concentration ranges:11
    • 4.5-10mmol/L: 0.8%
    • 10-20 mmol/L: 1.5%
    • >20 mmol/L: 3.5%
  • Cardiovascular benefits:
    • Fibrates only reduce non-fatal coronary events (19% relative risk reduction), with no benefit when added to statins.12
    • Statins reduce cardiovascular events (25-35% relative risk reduction) and all-cause mortality (10% relative risk reduction).13


Gilbert Bretecher June 15, 2023

lowering triglyceride of minimal benefit


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Blair J. MacDonald PharmD
  • Scott Garrison MD PhD CCFP
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. Preiss D, Tikkanen MJ, Welsh P, et al. L JAMA. 2012; 308(8):804-811.

2. Das Pradhan A, Glynn RJ, Fruchart JC, et al. N Engl J Med. 2022; 387(21):1923-1934.

3. Yadav D, Lowenfels AB. Pancreas. 2006 Nov; 33(4):323-305.

4. Hassanloo J, Béland-Bonenfant S, Paquette M, et al. J Clin Lipidol. 2022 Jul-Aug; 16(4):455-62.

5. Tenner S, Baillie J, DeWitt J, et al. Am J Gastroenterol. 2013 Sep; 108(9):1400-15; 1416.

6. Bodmer M, Brauchli YB, Krähenbühl S, et al. JAMA. 2009; 302(18):2001-2007.

7. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Dig Dis Sci. 2001; 46(3):540-544.

8. Coronary Drug Project Research Group. N Engl J Med. 1977; 296(21):1185-1190.

9. Berglund L, Brunzell JD, Goldberg AC, et al. J Clin Endocrinol Metab. 2012; 97(9):2969-2989.

10. Grundy SM, Stone NJ, Bailey AL, et al. J Am Coll Cardiol. 2019; 73(24):3168-3209.

11. Patel RS, Pasea L, Soran H, et al. Cardiovasc Diabetol. 2022; 21(1):102.

12. Turgeon RD, Allan M. Tools for Practice #97. Available at: https://cfpclearn.ca/tfp97/. Accessed on April 4, 2023.

13. Allan M, Lindblad AJ, Comeau A, et al. Can Fam Physician. 2015 Oct; 61(10):857-67, e439-50.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.